Koski S, Martinon-Torres F, Ramet M, Zolotas L, Newton R, Maansson R
Infect Dis Ther. 2025; 14(2):463-481.
PMID: 39883399
PMC: 11829884.
DOI: 10.1007/s40121-024-01098-8.
Villena R, Safadi M, Gentile A, Pujadas M, De la Maza V, George S
Vaccines (Basel). 2023; 11(12).
PMID: 38140244
PMC: 10748232.
DOI: 10.3390/vaccines11121841.
Subbarao S, Ribeiro S, Campbell H, Okike I, Ramsay M, Ladhani S
Lancet Reg Health Eur. 2023; 32:100692.
PMID: 37538400
PMC: 10393823.
DOI: 10.1016/j.lanepe.2023.100692.
Micoli F, Stefanetti G, MacLennan C
Front Mol Biosci. 2023; 10:1201693.
PMID: 37261327
PMC: 10227950.
DOI: 10.3389/fmolb.2023.1201693.
Ali M, Moses A, Nakua E, Punguyire D, Cheabu B, Avevor P
Clin Infect Pract. 2023; 16:100160.
PMID: 37206902
PMC: 10189849.
DOI: 10.1016/j.clinpr.2022.100160.
Meningococcal disease in North America: Updates from the Global Meningococcal Initiative.
Asturias E, Bai X, Bettinger J, Borrow R, Castillo D, Caugant D
J Infect. 2022; 85(6):611-622.
PMID: 36273639
PMC: 11091909.
DOI: 10.1016/j.jinf.2022.10.022.
Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa.
Viviani S
Vaccines (Basel). 2022; 10(4).
PMID: 35455366
PMC: 9027557.
DOI: 10.3390/vaccines10040617.
Meningococcal disease and vaccination in college students.
Schaffer DeRoo S, Torres R, Fu L
Hum Vaccin Immunother. 2021; 17(11):4675-4688.
PMID: 34613863
PMC: 8828137.
DOI: 10.1080/21645515.2021.1973881.
A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.
Ruiz Garcia Y, Abitbol V, Pellegrini M, Bekkat-Berkani R, Soumahoro L
Infect Dis Ther. 2021; 11(2):639-655.
PMID: 34591258
PMC: 8481757.
DOI: 10.1007/s40121-021-00519-2.
Exploring the Ability of Meningococcal Vaccines to Elicit Mucosal Immunity: Insights from Humans and Mice.
Currie E, Gray-Owen S
Pathogens. 2021; 10(7).
PMID: 34358056
PMC: 8308890.
DOI: 10.3390/pathogens10070906.
Crossing the Rubicon: A fine line between waiting and vaccinating adolescents against COVID-19.
Ladhani S
J Infect. 2021; 83(3):294-297.
PMID: 34302866
PMC: 8294773.
DOI: 10.1016/j.jinf.2021.07.015.
Invasive Meningococcal Disease, 2011-2020, and Impact of the COVID-19 Pandemic, England.
Subbarao S, Campbell H, Ribeiro S, Clark S, Lucidarme J, Ramsay M
Emerg Infect Dis. 2021; 27(9):2495-2497.
PMID: 34193335
PMC: 8386802.
DOI: 10.3201/eid2709.204866.
Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015-2016.
Marjuki H, Chang H, Topaz N, Whaley M, Vuong J, Chen A
mBio. 2021; 12(3).
PMID: 34006659
PMC: 8262942.
DOI: 10.1128/mBio.00855-21.
Seroprevalence of meningococcal serogroup C bactericidal antibodies in the Portuguese population, a decade after vaccine introduction in the National Immunisation Programme.
Goncalves P, Saez-Lopez E, Carneiro S, Simoes M
PLoS One. 2021; 16(4):e0250103.
PMID: 33857245
PMC: 8049472.
DOI: 10.1371/journal.pone.0250103.
A Narrative Review of the W, X, Y, E, and NG of Meningococcal Disease: Emerging Capsular Groups, Pathotypes, and Global Control.
Tzeng Y, Stephens D
Microorganisms. 2021; 9(3).
PMID: 33802567
PMC: 7999845.
DOI: 10.3390/microorganisms9030519.
Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs.
Htar M, Jackson S, Balmer P, Serra L, Vyse A, Slack M
BMC Public Health. 2020; 20(1):1890.
PMID: 33298015
PMC: 7724720.
DOI: 10.1186/s12889-020-09946-1.
Herd Protection against Meningococcal Disease through Vaccination.
Clark S, Borrow R
Microorganisms. 2020; 8(11).
PMID: 33126756
PMC: 7693901.
DOI: 10.3390/microorganisms8111675.
Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits.
Stawasz A, Huang L, Kirby P, Bloom D
Front Public Health. 2020; 8:261.
PMID: 32754566
PMC: 7366491.
DOI: 10.3389/fpubh.2020.00261.
Economic evaluation of meningococcal vaccines: considerations for the future.
Christensen H, Al-Janabi H, Levy P, Postma M, Bloom D, Landa P
Eur J Health Econ. 2019; 21(2):297-309.
PMID: 31754924
PMC: 7072054.
DOI: 10.1007/s10198-019-01129-z.
Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories.
Can Commun Dis Rep. 2019; 36(Suppl 2):1-35.
PMID: 31680692
PMC: 6798877.
DOI: 10.14745/ccdr.v36i00as2.
